Results 151 to 160 of about 11,970 (271)

Quality assessment of endotoxin contamination in consumables used for assisted reproductive technology. [PDF]

PLoS One
Tomari H, Sugizaki E, Ibrahim S, Hashiguchi Y, Koyama G, Nakamura Y, Nagata M, Nagata Y, Haishima Y.   +8 more
europepmc   +1 more source

Studies on Pyrogen. I. Isolation of Pyrogen

Nippon kagaku zassi, 1956
Shuichi Suzuki, Jun Mizuguchi
openaire   +2 more sources

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source

Validation of the Monocyte Activation Test Demonstrating Equivalence to the Rabbit Pyrogen Test. [PDF]

Int J Mol Sci
Burgmaier L, van den Berg J, Gajewi M, Röder R, Reich J, Deutschmann SM.   +5 more
europepmc   +1 more source

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM‐3

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Introduction Elranatamab, approved for relapsed or refractory multiple myeloma, demonstrated deep, durable responses and manageable safety in patients without prior B‐cell maturation antigen (BCMA)‐directed therapy (BCMA‐naive) in MagnetisMM‐3 (NCT04649359). This post hoc analysis evaluated efficacy and safety in the US subgroup.
Ajay K. Nooka, Christopher Strouse, Sarah M. Larson, Alexander Lesokhin, Asya Varshavsky‐Yanovsky, David H. Vesole, Guenther Koehne, Elpitha Soussou, Sharon T. Sullivan, Jay Cheng, Noopur Raje   +10 more
wiley   +1 more source

First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial

Cancer, Volume 132, Issue 11, 1 June 2026.
Envafolimab combined with recombinant human endostatin demonstrates favorable efficacy and tolerable toxicity in non–small cell lung cancer patients. MMP1 and TNFRSF6B may be predictive biomarkers for treatment response. Abstract Background This trial evaluates the efficacy and safety of combining envafolimab and recombinant human endostatin (Rh ...
Changhong Dong, Liang Liu, Yun Qiao, Mei Wang, Daan Song, Lihua Zhou, Yajun Ji, Yan Li, Fendou Ding, Hao Wang, Min Zhuang, Lei Wang, Zhenghong Liu, Haitao Fei, Xiangjun Guo, Baoxiang Bian, Chunluan Yuan, Guanghui Xu, Lijian Fang, Yan Li, Ziyan Song, Kaiyuan Hui, Xiaodong Jiang   +22 more
wiley   +1 more source

Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome

Epilepsia, Volume 67, Issue 6, Page 2796-2807, June 2026.
Overview of the phase 3 trial evaluating soticlestat as adjunctive therapy in children and young adults with Dravet syndrome. Abstract Objective This study evaluated the efficacy, safety, and tolerability of soticlestat as adjunctive therapy in children and young adults with Dravet syndrome (DS).
Joseph Sullivan, Kette Valente, Vicente Villanueva, Adam Strzelczyk, Rima Nabbout, Eiji Nakagawa, Yuehua Zhang, Marta Zolnowska, Yasir Khan, Cheng Dong, Samuel Hsiao, Sarah I. Sheikh, Philipp von Rosenstiel, Mahnaz Asgharnejad, Venkatesha Murthy   +14 more
wiley   +1 more source

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti‐C5 often experience extravascular hemolysis with anemia. Iptacopan, the first oral proximal complement inhibitor targeting factor B, has shown efficacy and safety in PNH patients. APPULSE‐PNH (NCT05630001), a phase 3b, single‑arm, open‐label trial, enrolled adult patients with PNH
Austin Kulasekararaj, Flore S. de Fontbrune, Anna Gaya, Ilene Weitz, David J. Kuter, Bhumika J. Patel, David J. Araten, Abhay Singh, Jun H. Jang, Richard J. Kelly, Eros Di Bona, Michael Loschi, Vinod Pullarkat, Jörg Schubert, Rosario Notaro, Mustafa N. Yenerel, Joan Beckman, Nicolas Blin, Irina Murakhovskaya, Jens Panse, Eloy Roman, Alexander Röth, Hubert Schrezenmeier, Srinivas Tantravahi, Régis P. de Latour, Navin Mahajan, Luca Monaco, Tao Ding, Tomasz Lawniczek, Philippe Ferber, Marion Dahlke, Antonio M. Risitano   +31 more
wiley   +1 more source

Structural and functional evolution of IL-1 targeting: From systemic neutralization to bioengineered nanotherapies. [PDF]

Mater Today Bio
Yang L, Chen G, Lyu Z.
europepmc   +1 more source

Impact of liquid dosing and associated cell 'drowning' in a 3D human bronchial epithelial model used for protease exposure studies. [PDF]

Front Toxicol
Hopkins G, Sheffield D, Barlow H, Lalljie A, Cochrane S, Fairclough LC.   +5 more
europepmc   +1 more source